Keytruda and Efti combination therapy achieved a median overall survival of 17.6 months in head and neck squamous cell carcinoma with PD-L1 CPS less than one. The combination therapy demonstrated a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback